Seehra Jasbir 4
4 · Keros Therapeutics, Inc. · Filed Feb 20, 2026
Research Summary
AI-generated summary of this filing
Keros Therapeutics CEO Jasbir Seehra Sells 7,015 Shares
What Happened
- Jasbir Seehra, CEO of Keros Therapeutics (KROS), sold 7,015 shares on 2026-02-19 at $16.17 per share, for proceeds of approximately $113,433. The filing reports this as a sale (code S).
Key Details
- Transaction date: 2026-02-19; Price: $16.17 per share; Shares sold: 7,015; Total: ~$113,433.
- Shares owned after the transaction: Not specified in the submitted excerpt of the filing.
- Footnote: The sale was part of the issuer’s automatic "sell-to-cover" policy to satisfy tax withholding on vested restricted stock units (RSUs); the sales were automatic and not at the insider’s discretion.
- Filing timeliness: Reported on 2026-02-20 for a 2026-02-19 transaction — appears to have been filed promptly.
Context
- This was a sale tied to tax withholding for RSU vesting (routine administrative transaction), not an open-market discretionary sale intended to express a view on the stock.
- For retail investors, routine sell-to-cover transactions are common and generally less informative about an insider’s sentiment than voluntary open-market purchases.
Insider Transaction Report
Form 4
Seehra Jasbir
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Sale
Common Stock
[F1]2026-02-19$16.17/sh−7,015$113,433→ 385,708 total
Footnotes (1)
- [F1]The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
Signature
/s/ Keith Regnante, Attorney-in-Fact|2026-02-20